Lung Cancer Awareness Month

A word from Biodesix CEO Scott Hutton | November 2, 2026

Lung Cancer Awareness Month

November marks an incredibly important month for Biodesix. It is Lung Cancer Awareness Month (LCAM, pronounced “el-cam”). Every year, this month reminds us why we do what we do and who we do it for. This year, however, I find myself reflecting on that purpose a little more deeply. 

Over the past several months, I have spent a great deal of time thinking about patients and families facing uncertainty, waiting for answers, and navigating some of the hardest moments of their lives. It has reinforced something that can be easy to lose sight of amid the demands of our day-to-day work: what we do matters in a very real and personal way. 

When someone’s health is in question, every day feels longer. Every unanswered question carries weight. Every piece of information can bring either relief or clarity about the path forward. In those moments, diagnostics are far more than science, technology, or a laboratory test result. They provide clarity when it is needed most. They help healthcare professionals make informed decisions. Most importantly, they help patients and families move forward with greater confidence and hope. 

Those reflections have given me an even deeper appreciation for the work happening across Biodesix every day. Whether you are serving patients, supporting customers, advancing innovation, running our laboratory, or enabling our business to operate, your work makes a difference. The commitment, expertise, and care you bring to your work help people during some of the most challenging and uncertain moments of their lives. 

This year, there is another reason to reflect on the impact of our work. 

In my eight years leading Biodesix, this is the first Lung Cancer Awareness Month in which healthcare professionals have access to a groundbreaking, expert-developed framework designed to help establish lung nodule programs focused on the early detection and diagnosis of lung cancer. The resource guide, Building a Lung Nodule Program: From Detection to Diagnosis, unveiled at CHEST 2026, recommends the use of clinically validated biomarkers as part of routine lung nodule risk triage to optimize patient care. It is a significant milestone not only for pulmonary nodule management, but for patients who deserve greater clarity and confidence when difficult decisions need to be made. 

For all of us at Biodesix, it also represents something more. It reflects a growing recognition that precision diagnostics can help healthcare professionals make more informed decisions, reduce uncertainty, accelerate appropriate care, and ultimately improve patient outcomes. That is exactly why Biodesix exists. 

I have always been proud to lead this company and this team. Lately, I have found myself feeling even more grateful. Grateful for our mission. Grateful for the impact we have on patients and families. And especially grateful for the people of Biodesix who bring that mission to life every day. 

As we recognize Lung Cancer Awareness Month, I encourage each of us to take a moment to remember why our work matters. Behind every sample, every report, every customer interaction, every innovation, and every operational task is a person and a family looking for answers. 

That responsibility is what makes our work meaningful. It is also what makes our mission worth pursuing every single day. 

Please also take time to care for yourselves and the people you love. Health, family, and time together are gifts that can be easy to take for granted until they are tested. 

Thank you for your commitment to our mission, to our healthcare professional customers and their patients, and to one another. Together, we are helping create a future where more patients receive answers sooner, make more informed decisions, and have a better chance at better outcomes.